Publications by authors named "H Kameoka"

Strigolactones (SLs) are a class of plant hormones that regulate many aspects of plant growth and development. SLs also improve symbiosis with arbuscular mycorrhizal fungi (AMF) in the rhizosphere. Recent studies have shown that the DWARF14-LIKE (D14L)/KARRIKIN-INSENSITIVE2 (KAI2) family, paralogs of the SL receptor D14, are required for AMF colonization in several flowering plants, including rice.

View Article and Find Full Text PDF

Karrikins are smoke-derived butenolides that induce seed germination and photomorphogenesis in a wide range of plants. KARRIKIN INSENSITIVE2 (KAI2), a paralog of a strigolactone receptor, perceives karrikins or their metabolized products in Arabidopsis thaliana. Furthermore, KAI2 is thought to perceive an unidentified plant hormone, called KAI2 ligand (KL).

View Article and Find Full Text PDF

Osmotic stresses, such as drought and high salinity, adversely affect plant growth and productivity. The phytohormone abscisic acid (ABA) accumulates in response to osmotic stress and enhances stress tolerance in plants by triggering multiple physiological responses through ABA signaling. Subclass III SNF1-related protein kinases 2 (SnRK2s) are key regulators of ABA signaling.

View Article and Find Full Text PDF

Legumes develop root nodules in association with compatible rhizobia to overcome nitrogen deficiency. Rhizobia enter the host legume, mainly through infection threads, and induce nodule primordium formation in the root cortex. Multiple transcription factors have been identified to be involved in the regulation of the establishment of root nodule symbiosis, including ERF Required for Nodulation1 (ERN1).

View Article and Find Full Text PDF
Article Synopsis
  • Palbociclib (PAL) is a targeted therapy for estrogen receptor-positive and HER2-negative recurrent breast cancer, often used alongside other endocrine treatments.
  • A study found that patients with higher levels of white blood cells (WBC), neutrophils (Neu), and lymphocytes (Lym) experienced longer treatment durations when on PAL, suggesting these blood cell counts could influence treatment success.
  • The median time-to-treatment failure (TTF) was 5.6 months, with differences noted between groups receiving fulvestrant (FUL) and aromatase inhibitors (AI), though not all differences were statistically significant, indicating more research is needed in this area.
View Article and Find Full Text PDF